Parnassus Investments Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$842M |
| 2 |
Eli Lilly
LLY
|
+$772M |
| 3 |
Ferguson
FERG
|
+$635M |
| 4 |
Workday
WDAY
|
+$531M |
| 5 |
KLA
KLAC
|
+$393M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Salesforce
CRM
|
+$705M |
| 2 |
Oracle
ORCL
|
+$658M |
| 3 |
NVIDIA
NVDA
|
+$581M |
| 4 |
Mondelez International
MDLZ
|
+$489M |
| 5 |
Sysco
SYY
|
+$486M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.97% |
| 2 | Financials | 14.46% |
| 3 | Consumer Discretionary | 13.45% |
| 4 | Industrials | 12.23% |
| 5 | Healthcare | 12.2% |
Similar funds
Parnassus Investments's Q4 2024 Portfolio in Review
As of Q4 2024, Parnassus Investments held 132 positions worth $45B, down 4.5% from $47.1B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Parnassus Investments withdrew a net $1.82B in Q4 2024, closing 6 positions and reducing 74 holdings. Its most notable exit was Mondelez International, an estimated $489M position sold in full.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 31% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Parnassus Investments opened a new position in Vertex Pharmaceuticals worth $731M.
- Parnassus Investments's largest Q4 2024 buy was Vertex Pharmaceuticals: 1,815,950 shares worth $731M.
- Parnassus Investments added most to Eli Lilly in Q4 2024, an estimated $772M increase.
- Parnassus Investments's biggest Q4 2024 reduction was Salesforce, cutting an estimated $705M.
- Parnassus Investments fully exited Mondelez International in Q4 2024, selling an estimated $489M.
- Parnassus Investments's ten largest holdings make up 37% of its $45B portfolio in Q4 2024.
- Parnassus Investments opened 6 new positions and closed 6 in Q4 2024.
- Parnassus Investments's portfolio value fell 4.5% quarter-over-quarter to $45B.
Based on Parnassus Investments's 13F filing for Q4 2024, filed 10 Feb 2025.